Using race in clinical research to develop tailored medications. Is the FDA encouraging discrimination or eliminating traditional disparities in health care for African Americans?
Ruel
Michael D
MD
Southern Illinois University School of Law, Carbondale, USA.
D001741:Black or African American / Q000235:genetics*; D002985:Clinical Protocols; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004338:Drug Combinations; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D015507:Drugs, Investigational; D006333:Heart Failure / Q000188:drug therapy / Q000208:ethnology; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D018579:Patient Selection; D010597:Pharmacogenetics / Q000331:legislation & jurisprudence*; D011287:Prejudice; D012959:Socioeconomic Factors; D035521:Supreme Court Decisions; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D014665:Vasodilator Agents / Q000627:therapeutic use
D004338:Drug Combinations; D015507:Drugs, Investigational; D014665:Vasodilator Agents; C431665:isosorbide-hydralazine combination; D006830:Hydralazine; D007548:Isosorbide Dinitrate